Oxygen Biotherapeutics Sends Letter to Holds, Discusses Progress, Prelim. Results in Trials

Oxygen Biotherapeutics, Inc., (“OBI”) OXBT a developer of oxygen-carrying therapeutics, today announced the Company has issued a Letter to Shareholders. Highlights of the letter include: * Progress in our international Phase IIb clinical trials of Oxycyte® for the treatment of traumatic brain injury, a global market projected to reach $2 billion by 2017 according to GlobalData * Preliminary results from our preclinical trials of Oxycyte® in the U.S., designed to address the FDA's clinical hold * Implementation of our business strategy to focus on the development of Oxycyte® for critical indications while out-licensing non-core indications * Improved cash position resulting from a $5.4 million funding closed in July which provides liquidly to fund projected operating requirements and clinical trials through the remainder of fiscal 2014 * The U.S. Army and U.S. Navy's Cooperative Research & Development Agreements to explore Oxycyte® * Out-licensed Dermacyte® cosmetics line to Valor, which has generated licensing revenues and reduced our operating expenses * Our research partnership with Aurum Biosciences for the development of Oxycyte® for the diagnosis and treatment of stroke, a market projected to grow to $3.6 billion by 2015 according to GlobalData To read the letter in full please visit: http://www.oxybiomed.com/investors.html
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!